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Abstract To date, the identification of patients and earn­
ers of the fragile X syndrome has been earned out by 
DNA analysis by means of the polymerase chain reaction 
and Southern biot analysis. This direct DNA analysis al­
lows both the size of the CGG repeat and inethylation sta­
tus of the FMRI gene to be determined. We have recently 
presented a rapid antibody test on blood smears based on 
the presence of FMRP, the protein product of the FMRI 
gene, in lymphocytes from normal individuals and the ab­
sence of FMRP in lymphocytes from patients. Here, we 
have tested the diagnostic value of this new technique by 
studying FMRP expression in 173 blood smears from nor­
mal individuals and fragile X patients. The diagnostic 
power of the antibody test is “perfect” for males, whereas 
the results are less specific for females.
Introduction
Fragile X syndrome is the most frequent form of inherited 
mental retardation in humans and has a prevalence of ap­
proximately 1:4000 males and 1:6000 for females (Turner 
et al. 1996). The clinical symptoms are moderate to pro­
found mental retardation, macroorchidism and minor dys­
morphic features, and specific behavioral characteristics 
(Hagerman 1996). The identification of the mutational 
mechanism underlying the fragile X syndrome, an expan­
sion of the CGG repeat within exon 1 of the FMRI gene,
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has resulted in the development of a reliable diagnostic 
method by using direct DNA analysis (Oberle et al. 1991; 
Oostra et al. 1993; Rousseau et al. 1991; Verkerk et al. 
1991). The CGG repeat is polymorphic in the normal pop­
ulation and varies from 6-53 repeats, with a mean of 30 
repeats (Fu et al. 1991). In normal transmitting males and 
unaffected female carriers, a repeat length between 43 and 
200 (premutation) is observed, whereas in patients with 
the fragile X syndrome, an expansion of more than 200 
CGG repeats (full mutation) is found. The length of the 
repeat can be determined by polymerase chain reaction 
(PCR) analysis of the DNA from cells, e.g., white blood 
cells. However, only the size of the CGG repeat within the 
normal and premutation range can be investigated in this 
way. The reliable detection of a full mutation can only be 
obtained by Southern blot analysis (Oostra et al. 1993; 
Rousseau et al. 1991). The gross expansion in repeat num­
ber usually coincides with hypermethylation of the repeat 
and the CpG island proximal to the gene (Hansen et al. 
1992; Sutcliffe et al. 1992). Methylation is associated 
with silencing of the FMRI gene, thus preventing protein 
production (Devys et al. 1993; Verheij et al. 1993). The 
absence of the FMRI protein is now well established as 
causing fragile X syndrome.
We have developed a new diagnostic test involving the 
use of monoclonal antibodies against the protein product 
of the FMRI gene, FMRP. This rapid test is performed on 
blood smears and thus needs only one drop of blood 
(Willemsen et al, 1995). Recently, a similar test with which 
we have been able to identify the lack of FMRP in fetuses 
with a full mutation has been described for chorionic villi 
(Willemsen et al. 1996). In blood smears from control in­
dividuals and carriers with a premutation, FMRP can be 
detected in the cytoplasm of lymphocytes, whereas the 
lymphocytes of male fragile X patients are devoid of 
FMRP, because of lack of transcription caused by the hy­
permethylation of the promoter region of the FMRI gene. 
Interestingly, we have frequently observed FMRP expres­
sion in some lymphocytes from affected males, suggest­
ing the presence of a premutation in these positively la­
beled cells. This phenomenon can be expected because of
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the mosaic DNA pattern found in over 50%  of affected 
males (De Graaff et al. 1995; Rousseau et al. 1991). In our 
initial report, we have also described a female carrier who 
had a full FMRI mutation and who showed expression of 
FMRP in approximately 50% of her lymphocytes. Appar­
ently, random inactivation of the X-chromosome had oc­
curred in the lymphocytes of this carrier, because only the 
transcription of the FMRI gene on the active “normal” X- 
chromosome would result in expression of FMRP. How­
ever, these results were based on a limited number of pa­
tients and control individuals. In this study, we report the 
evaluation of the antibody test by determination of FMRP 
expression in 173 blood smears from healthy individuals 
and fragile X patients with a full mutation.
Materials and methods
Mouse monoclonal antibodies against FMRP were generated in a 
so-called Tecno-mouse system by using specific hybridoma clone 
lC3-la. This antibody or the commercially available crude ascites 
fluid (1:1600; Euromedex, France) was used.
Blood smears were made within 6 h after sampling of the 
blood, air-dried, sealed in Saran Wrap, and stored at-80°C. Alter­
natively, smears were stored at room temperature in a slide box. 
Immuno-incubation of the smears was performed as described 
(Willemsen et al. 1995) with an indirect alkaline phosphatase tech­
nique (see Fig. 1). Smears were counterstained with hematoxylin 
and examined with a Zeiss Axioskop 20. Detailed information 
concerning this immunocytochemical technique can be found on 
the Internet at http://www.eur.nl/FGG/CH 1/fragx/.
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1 = specific antibody
2 = secondary antibody conjugated with biotin 
- avidin
V
= alkaline phosphatase
Fig-1 Schematic presentation of the indirect alkaline phosphatase 
technique. The three-step immunolabeling procedure is followed 
by a substrate (New Fuchsine) incubation, resulting in a red reac­
tion product
Table 1 Percentage of lymphocytes showing FMRP expression in 
blood smears from males and females {normal and retarded). The 
average mean and SD are shown
Repeat length
Normal Full mutation
Males Mean 89 7
SD 9 7
n 33 69
Females Mean 80 39
SD 6 19
n 27 44
We tested 33 males with a normal FM RI allele and 69 males 
who had a full mutation and who were mentally retarded. These 
numbers were 27 and 44, respectively, for females.
Results
Immuno-incubation and analysis of the blood smears was 
performed in two different laboratories. Good results were 
recently obtained by making smears immediately after 
blood sampling and storage at room temperature for a 
maximum period of three weeks, making this storage pro- 
tocol preferable to that of frozen smears. However, for 
standardization of the technique in both laboratories, the 
results in this report are based on blood smears that were 
stored at -80° C. In every blood smear, 100 lymphocytes 
were examined and scored for the presence of reaction 
product, viz., FMRP. The numbers of lymphocytes la­
beled for FMRP were expressed as a percentage of the to­
tal lymphocytes examined. The mean and SD of the per­
centages of FMRP expression in the different groups are 
given in Table I.
Two groups of males and females were identified based 
on their mutational and mental status. The mentally re­
tarded individuals that were studied in this report had pre­
viously been diagnosed for fragile X syndrome by DNA 
analysis, and all showed a full mutation. Briefly, no sig­
nificant differences were found between the means of nor­
mal males [n = 33) and normal females (n = 27), which 
were 89% and 80%, respectively, whereas mentally re­
tarded males with a full mutation (n = 69) and affected fe­
males with a full mutation (n = 44) showed significantly 
lower means of 7% and 39%, respectively. The antibody 
test for diagnosing fragile X syndrome is meant to give an 
accurate positive or negative test result. Such di- 
chotomization is inherent with respect to clinical practice 
of the fragile X syndrome. In the blood smears, we ob­
served variability in the number of FMRP-expressing 
lymphocytes in the various control individuals and fragile 
X patients. We plotted the distribution of the percentage 
of FMRP expression in normal and retarded male and fe­
male individuals (Fig. 2). For males, the diagnostic power 
of the test is “perfect”, because there is no overlap be­
tween the values of normal males and retarded males with 
a full mutation (Fig. 2A). For females, there is some over-
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Fig.2 FMRP distribution in
males (A) and females (H), in 
every blood smear, 100 lym­
phocytes were examined. The 
percentage of FMRP expres­
sion is depicted in categories 
(À-t/A/.vj, whereas the Y-axis il­
lustrates the percentage of pa­
tients for each category
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lap of the percentages in the two different groups (Fig. 
2B), although this is not an indication that this antibody 
test is unsuitable for diagnostic purpose.
In clinical practice, a cut-off point is used for diagnos­
tic tests» Below the cut-off point, the individual is sus­
pected as being affected with the fragile X syndrome. In 
all other cases, the individual is excluded from having a 
full mutation. Sensitivity should be 100% for a reliable di­
agnostic test. Therefore, we have chosen the maximum 
FMRP expression found in fragile X patients as the cut­
off point. Because of the accuracy of the detection FMRP 
expression, the upper limit of the 95% confidence interval 
for this maximum FMRP expression, based on 100 lym­
phocytes, has been taken. For males, the cut-off point has 
been determined to be 42% and for females 83%. By us­
ing these cut-off points, the sensitivity is 100% for both 
males and females. The specificity is 100% for males and 
41% for females.
A second question that should be addressed is the num­
ber of lymphocytes that should be examined to establish 
FMRP expression sufficiently accurately for diagnostic 
use. Less than a 0.1% misciassification of the full mutation 
has been used as a criterion. The following procedure has 
been employed to calculate the percentage misclassified 
when using n lymphocytes. For a carrier, the probability 
of being misclassified can be calculated by using a bino­
mial distribution with parameters n and probability P, by 
taking the FMRP expression in the 100 investigated lym­
phocytes. The percentage misclassified is the sum of these 
probabilities, summing over all full mutation carriers. By 
using this best cut-off point for males (42%), a reliable 
test result can be obtained by counting 80 lymphocytes; 
for females (83%), 50 lymphocytes should be examined.
Discussion
To date, the identification of patients with the fragile X 
syndrome has been carried out by using a combination of 
a direct DNA test by PCR analysis and Southern blotting. 
For screening large numbers of individuals, this method is 
inconvenient, because the technique is time-consuming. 
The recent development of a rapid antibody test for diag­
nosing fragile X syndrome enables the detection of fragile 
X patients in large screening programs. However, a vali­
dation of this new test should be performed before its im­
plementation in clinical practice. Here, we present an 
evaluation of this antibody test on blood smears of a large 
group of individuals (n = 173), including fragile X patients 
(n = 113), as carried out in two independent laboratories.
In males, statistical analysis of the data confirms the 
high sensitivity of the FMRP test, as previously suggested
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in the original report in which a limited number of pa­
tients was investigated (Willemsen et al. 1995). DNA 
analysis by Southern analysis of white blood cells from 
affected males previously revealed the presence of a full 
mutation and premutation in some patients (n = 5; mo­
saic). This has been confirmed by the antibody test, which 
shows FMRP expression in some of their lymphocytes. 
No overlap should exist between patients and controls. 
The data from affected males show a high specificity for 
all patients studied. This implies that the FMRP test can 
discriminate between affected and normal males on the 
basis of FMRP expression in lymphocytes. Nevertheless, 
carriers with a premutation cannot be detected with this 
antibody test, because they express normal amounts of 
FMRP in their lymphocytes (Feng et al. 1995). However, 
premutations can be detected by PCR analysis and South­
ern blot analysis. In females, the results of the antibody 
test in blood smears are less specific because of an over­
lap of the values in this patient group and the controls.
The values of FMRP-expressing lymphocytes in blood 
smears from males show a higher discriminating power 
than those from females. The best cut-off point for males 
is 42% positive labeled lymphocytes and for females 83% 
positive labeled lymphocytes. Thus, no female with the 
fragile X syndrome will be missed, but approximately 
45% of the smears from healthy females with a normal re­
peat length will also show a value below 83%, giving in a 
large number of possible fragile X patients (false-positive 
test results). It is essential to confirm a positive antibody 
test result in the identified patients via a DNA test. Al­
though this seems to make the test less suitable for fe­
males, the majority of the samples from females can be 
excluded before DNA testing.
In addition, the storage of smears at room temperature 
for a maximum period of three weeks is an important step 
toward routine application of the antibody test for diag­
nosing fragile X syndrome. This enables preparation of 
the blood smears and subsequent transport of the slides by 
regular mail. Finally, all blood samples have been inde­
pendently tested in a second laboratory. Although the re­
sults of the two laboratories are similar, this has taken 
some time to achieve. The main cause for this problem 
has been the use, in one laboratory, of the commercial an­
tibody, which gives higher backgrounds than the Tecno- 
antibody used in the other laboratory, making the inter­
pretation of the test more difficult. However, a new dilu­
tion scheme of 1:1600 of the commercial antibody now 
gives reliable results. Furthermore, recognition of the dif­
ferent types of white blood cells by microscopy initially 
proved problematic.
In conclusion, the rapid antibody test enables normal 
and affected males to be discriminated, making this test 
extremely suitable for screening males in, for example, in­
stitutes for the mentally handicapped or schools for chil­
dren with learning disabilities. All identified patients have 
to be referred to a clinical genetics center to allow genetic 
counseling of the family involved. Further evaluation will 
automatically include DNA analysis for earner detection.
In theory, the antibody test may also be used for screen­
ing every newborn male for fragile X syndrome. Al­
though no technical obstacles for neonatal screening are 
present, ethical issues remain to be resolved before such a 
screening program can be started. Furthermore, after iden­
tifying patients in this way, DNA testing and adequate ge­
netic counseling facilities will again be necessary to iden­
tify carriers of the fragile X mutation in these families.
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